Neutrophil/Leukemia-Tropic Dual-Drug Nanomedicine Potentiates the Treatment of Acute Myeloid Leukemia

Scientists reported a neutrophil/leukemia-tropic polymersome vincristine/volasertib dual-drug nanoformulation to selectively bind to leukemia cells and neutrophils, and to ratiometrically release clinical chemotherapeutics and a polo-like kinase 1 inhibitor, thereby potentiating the treatment of AML.